Article
Engineering, Multidisciplinary
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
Summary: The development of Disease Risk Comorbidity Index (DRCI) based on Disease Risk Index (DRI) and Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) allows for effective risk stratification of patients receiving haploidentical hematopoietic stem cell transplantation. The DRCI accurately predicts disease-free survival, particularly in disease-specific subgroups such as acute leukemia patients. This index also shows predictive value for relapse, non-relapse mortality, overall survival, and can aid in identifying patients who will benefit most from the transplantation procedure.
Article
Cell & Tissue Engineering
Dylan Barth, Michael Singleton, Gregory Monohan, Brian McClune, Val Adams
Summary: This study retrospectively reviewed data from 181 autologous hematopoietic stem cell transplant patients and found that the HCT-CI cannot predict length of hospitalization or utilization of the ICU in autologous transplant patients. Patients with higher HCT-CI scores may incrementally utilize more resources.
CELL TRANSPLANTATION
(2022)
Article
Hematology
Marta Pena, Maria Queralt Salas, Alberto Mussetti, Gabriel Moreno-Gonzalez, Anna Bosch, Beatriz Patino, Laura Jimenez, Meriem Kara, Rocio Parody, Anna Sureda
Summary: The study demonstrates that EASIX-PRE can predict ICU admission, overall survival, and nonrelapse mortality in patients undergoing alloHCT. Analyzing EASIX-PRE values can help identify high-risk patients, allowing for early recognition and personalized intervention to improve outcomes.
Article
Immunology
Sophie Servais, Frederic Baron, Chantal Lechanteur, Laurence Seidel, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, Johan Maertens, Xavier Poire, Wilfried Schroyens, Carlos Graux, Ann De Becker, Pierre Zachee, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin
Summary: BM-derived MSC from a third-party donor appeared to improve hematological function after alloHCT, but comparative studies are needed to confirm these results.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Nicolas Fattinger, Jan A. Roth, Helen Baldomero, Daiana Stolz, Michael Medinger, Dominik Heim, Michael Tamm, Jorg P. Halter, Jakob R. Passweg, Martina Kleber
Summary: This study validated the use of the revised Pretransplant Assessment of Mortality (rPAM) score as a prognostic tool in a real-world cohort of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The results showed that the rPAM score was significantly associated with overall survival and nonrelapse mortality in these patients.
Article
Biophysics
Mouhamed Yazan Abou-Ismail, Gayathri Ravi, Pingfu Fu, Shufen Cao, Sowjanya Vuyyala, Paolo Caimi, Merle Kolk, Nicole Ferrari, Kirsten Boughan, Brenda Cooper, Molly Gallogly, Folashade Otegbeye, Benjamin Tomlinson, Marcos de Lima, Leland Metheny
Summary: Allogeneic hematopoietic cell transplant is an effective treatment for blood diseases, but drug use may lead to adverse outcomes. A retrospective analysis of 232 patients found that drug use was associated with increased non-relapse mortality, suggesting further research with larger cohorts is needed to validate these findings.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Ramzi Abboud, Fei Wan, Jacopo Mariotti, Marcos Arango, Luca Castagna, Rizwan Romee, Mehdi Hamadani, Saurabh Chhabra
Summary: The haploidentical related donor transplantation (haplo-HCT) is associated with cytokine release syndrome (CRS). The study identified several risk factors for the severity of CRS after haplo-HCT, including recipient CMV sero-positivity, prior transplant, HCT-CI score, and donor-recipient sex mismatch. Overall survival was found to be better with mild CRS and worse with severe CRS, with differing effects on relapse risk and non-relapse mortality between the two groups.
BONE MARROW TRANSPLANTATION
(2021)
Article
Nutrition & Dietetics
R. Toenges, H. Greinix, A. Lawitschka, J. Halter, A. Baumgartner, A. Simon, J. Arends, P. Jaeger, M. Middeke, I. Hilgendorf, S. Klein, E. M. Wagner-Drouet, C. Schmid, G. Bug, D. Wolff
Summary: The study investigates the clinical practice of nutritional treatment after alloHSCT, revealing variability in nutritional approaches and indicating a need for more high-quality data to support evidence-based nutrition for patients.
CLINICAL NUTRITION
(2021)
Article
Immunology
Alexandra Laberko, Ekaterina Deordieva, Gergely Krivan, Vera Goda, Saleh Bhar, Yuta Kawahara, Kanchan Rao, Austen Worth, David H. McDermott, Dmitry Balashov, Alexey Maschan, Anna Shcherbina
Summary: Research has shown that HSCT is effective in treating WHIM syndrome by correcting neutropenia and immunodeficiency, improving autoimmune diseases, and resolving infection symptoms.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Sang Hoon Yeon, Myung-Won Lee, Pham Thi Thuy Duong, Sora Kang, Sungju Jee, So-Young Ahn, Hyewon Ryu, Hyo-Jin Lee, Jung Hye Kwon, Hwan-Jung Yun, Deog-Yeon Jo, Ik-Chan Song
Summary: The composite HCT-CI/CPET score can predict the survival and mortality of patients with hematological malignancies who undergo allogeneic HSCT.
INTEGRATIVE CANCER THERAPIES
(2022)
Article
Biophysics
Asmita Mishra, Joseph Pidala, Ram Thapa, Brian C. Betts, Hugo Fernandez, Frederick L. Locke, Taiga Nishihori, Lia Perez, Xuefeng Wang, Claudio Anasetti, Heather Jim
Summary: This prospective study on adult allogeneic hematopoietic cell transplantation recipients showed that the 6-minute walk test on day +30 post-transplant had the greatest impact on subsequent survival and non-relapse mortality. The findings suggest the importance of focusing on rehabilitation and physical activity for patient survival.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Daniel Wolff, Philipp Y. Herzberg, Anne Herrmann, Steven Z. Pavletic, Pia Heussner, Friederike Mumm, Christina Hoefer, Inken Hilgendorf, Philipp G. Hemmati, Ernst Holler, Hildegard Greinix, Sandra A. Mitchell
Summary: This study developed a standardized Post-transplant Multimorbidity Index (PTMI), with results showing that chronic graft-versus-host disease (cGvHD) was significantly associated with PTMI, while age and prior acute GvHD were not.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Rebeca Bailen, Jose Luis Vicario, Laura Solan, Irene Sanchez-Vadillo, Pilar Herrera, Maria Calbacho, Raquel Alenda, Jose Luis Lopez-Lorenzo, Karem Humala, Anabelle Chinea, Jose Sanchez-Pina, Antonio Balas, Miguel Angel Moreno, Javier Arzuaga, Virginia Pradillo, Nieves Dorado, Gillen Oarbeascoa, Javier Anguita, Jose Luis Diez-Martin, Mi Kwon
Summary: This study reports the experience of using desensitization treatments for patients with DSAs undergoing haplo-HSCT. The results show that utilizing desensitization strategies guided by DSAs intensity kinetics can effectively decrease DSA intensity and improve engraftment rates.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Eun Hee Jung, Ja Min Byun, Dong-Yeop Shin, Young Rok Do, Jae-Cheol Jo, Sang Min Lee, Sung-Soo Yoon
Summary: The use of Lenograstim, a glycosylated recombinant form of G-CSF, effectively mobilizes hematopoietic progenitor cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant. The majority of patients achieved the target CD34+ cell collection with subcutaneous administration of Lenograstim. The study demonstrates the safety and efficacy of Lenograstim in MM autologous settings.
Article
Oncology
Nicolas Boissel, Patrice Chevallier, Vadim Doronin, Laimonas Griskevicius, Alexey Maschan, James McCloskey, Alessandro Rambaldi, Giuseppe Rossi, Andrey Sokolov, Ulla Wartiovaara-Kautto, Corina Oprea, Giovanni Abbadessa, Alice Gosselin, Sandrine Mace, Xavier Thomas
Summary: This study aimed to evaluate the efficacy and safety of Isatuximab monotherapy in patients with relapsed or refractory T-ALL or T-LBL. However, the results showed low efficacy of Isatuximab, with most patients experiencing disease progression and treatment-related adverse events.
Article
Oncology
Maria Teresa Voso, Felicetto Ferrara, Sara Galimberti, Alessandro Rambaldi, Adriano Venditti
Summary: This study explores the diagnostic approaches to AML in Italy using an online Delphi-based process, emphasizing the importance of genetic evaluation for classification and risk stratification. The study suggests that karyotyping, fluorescence in situ hybridization, and molecular tests should be performed in every AML case. Italian specialists also highlight the role of multidisciplinary diagnostics for AML.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biophysics
Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Victoria Potter, Ana Berceanu, Alessandro Rambaldi, Inken Hilgendorf, Nicolaus Kroeger, Stephan Mielke, Tsila Zuckerman, Jaime Sanz, Alessandro Busca, Hakan Ozdogu, Achilles Anagnostopoulos, Bipin Savani, Sebastian Giebel, Ali Bazarbachi, Alexandros Spyridonidis, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of treosulfan plus fludarabine and busulfan in different patient groups, and found that busulfan had better outcomes in younger patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfo, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuellar-Garcia, Juan Gonzalo Correa, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Shaimaa El-Ashwah, Alicia Enrico, Blanca Espinet, Lucia Farina, Angela Ferrari, Myriam Foglietta, Alberto Lopez-Garcia, Jose A. Garcia-Marco, Rocio Garcia-Serra, Massimo Gentile, Eva Gimeno, Maria Gomes da Silva, Odit Gutwein, Yervand K. Hakobyan, Yair Herishanu, Jose Angel Hernandez-Rivas, Tobias Herold, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga B. Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Maya Koren-Michowitz, Jorge Labrador, Deepesh Lad, Luca Laurenti, Alberto Fresa, Mark-David Levin, Carlota Mayor Bastida, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Raquel Nunes, Jacopo Olivieri, Miguel Arturo Pavlovsky, Inga Piskunova, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Gianluigi Reda, Gian Matteo Rigolin, Amit Shrestha, Martin Simkovic, Svetlana Smirnova, Martin Spacek, Paolo Sportoletti, Oana Stanca, Niki Stavroyianni, Doreen Te Raa, Kristina Tomic, Sanne Tonino, Livio Trentin, Ellen Van der Spek, Michel van Gelder, Marzia Varettoni, Andrea Visentin, Candida Vitale, Vojin Vukovic, Ewa Wasik-Szczepanek, Tomasz Wrobel, Lucrecia Yanez San Segundo, Mohamed Yassin, Marta Coscia, Alessandro Rambaldi, Emili Montserrat, Robin Foa, Antonio Cuneo, Marc Carrier, Paolo Ghia, Kostas Stamatopoulos
Summary: This retrospective multicenter study found that CLL patients with severe COVID-19 are at a high risk of thrombosis if thromboprophylaxis is not used, but also at increased risk of bleeding under the LMWH intermediate/therapeutic dose administration.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Meeting Abstract
Hematology
Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Maria Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno, Andrea Patriarca, Haifa Kathrin Al-Ali, Marcio Andrade, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro, Jean-Jacques Kiladjian, Estefania Bolanos, Florian H. Heidel, Keina Quiroz, Martin Griesshammer, Valentin Garcia Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues, Rajko Kusec, Blanca Xicoy, Margarita Guenova, Begona Navas, Anna Angona, Edyta Cichocka, Anna Masternak, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro M. Vannucchi
Meeting Abstract
Hematology
Benedetta Rambaldi, Stefania Galimberti, Giuliana Rizzuto, Chiara Francesca Magnani, Chiara Buracchi, Giulia Risca, Martina Paredi, Daniela Belotti, Alex Moretti, Marianna Ponzo, Sarah Tettamanti, Gian Maria Borleri, Cristian Meli, Muriel Paganessi, Silvia Zaninelli, Elisa Gotti, Chiara Capelli, Martino Introna, Federico Lussana, Giuseppe Gritti, Silvia Ferrari, Anna Grassi, Sara Napolitano, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi, Giuseppe Gaipa
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Alberto Biggi, Stephane Chauvie, Federico Fallanca, Luca Guerra, Fabrizio Bergesio, Massimo Menga, Andrea Bianchi, Michele Gregianin, Agostino Chiaravalloti, Orazio Schillaci, Chiara Pavoni, Caterina Patti, Marco Picardi, Alessandra Romano, Corrado Schiavotto, Roberto Sorasio, Simonetta Viviani, Giorgio La Nasa, Livio Trentin, Alessandro Rambaldi, Andrea Gallamini
Summary: This study demonstrates the accuracy of end-of-treatment FDG-PET/CT in predicting treatment outcome in lymphoma patients, and confirms the appropriateness of the Lugano classification for evaluation.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Nicolas Boissel, Sabina Chiaretti, Cristina Papayannidis, Josep-Maria Ribera, Renato Bassan, Andrey N. Sokolov, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Gerhard Zugmaier, Robin Foa, Alessandro Rambaldi
Summary: This retrospective study included adult patients with B-cell ALL who were treated with blinatumomab for MRD+ or R/R B-cell ALL. The results showed significant treatment responses and survival benefits in both groups of patients.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Pierola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin--Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D'Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Francesc Sole, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, Maria Diez--Campelo, Matteo G. Della Porta
Summary: This study aimed to describe sex diversity in myelodysplastic syndromes and incorporate sex information into clinical decision-making. The study found differences between men and women in terms of disease genotype, phenotype, and clinical outcomes. Moreover, new prognostic models that included sex information were developed and performed better than the revised International Prognostic Scoring System.
LANCET HAEMATOLOGY
(2023)
Review
Oncology
Federico Lussana, Gianluca Cavallaro, Pantaleo De Simone, Alessandro Rambaldi
Summary: In this review, the impact of novel immune therapies on the treatment of acute lymphoblastic leukemia (ALL) in children and adults was discussed. Results from trials evaluating the incorporation of these new drugs into frontline treatments show promising clinical benefit. Clinical conditions, such as high tumor burden or extra medullary relapse, still have poor clinical outcome despite the promising results. Combination of immunotherapies with chemotherapy in frontline treatment is being evaluated to increase the rate and depth of molecular remission. The use of tyrosine kinase inhibitors and immunotherapy in Ph-positive ALL has shown unprecedented rates of remission and long-term cure. The development of potentially curative treatment modalities for older ALL patients who cannot receive intensive chemotherapy is also highlighted.
Article
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, GianMaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
Summary: DNA methylation patterns in sparse CpG regions drive chemoresistance in Acute Myeloid Leukemia patients.
COMMUNICATIONS BIOLOGY
(2023)
Correction
Biology
Alberto Magi, Gianluca Mattei, Alessandra Mingrino, Chiara Caprioli, Chiara Ronchini, Gianmaria Frige, Roberto Semeraro, Davide Bolognini, Alessandro Rambaldi, Anna Candoni, Emanuela Colombo, Luca Mazzarella, Pier Giuseppe Pelicci
COMMUNICATIONS BIOLOGY
(2023)
Article
Multidisciplinary Sciences
Gabriele Casirati, Andrea Cosentino, Adele Mucci, Mohammed Salah Mahmoud, Iratxe Ugarte Zabala, Jing Zeng, Scott B. Ficarro, Denise Klatt, Christian Brendel, Alessandro Rambaldi, Jerome Ritz, Jarrod A. Marto, Danilo Pellin, Daniel E. Bauer, Scott A. Armstrong, Pietro Genovese
Summary: Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting protein function or regulation, enabling the targeting of genes that are essential for leukaemia survival and reducing the risk of tumour immune escape.
Letter
Oncology
Alessandra Carobbio, Alessandro Maria Vannucchi, Elisa Rumi, Valerio De Stefano, Alessandro Rambaldi, Giuseppe Carli, Maria Luigia Randi, Heinz Gisslinger, Francesco Passamonti, Juergen Thiele, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui
BLOOD CANCER JOURNAL
(2023)